Compared to EPZ6438 and GSK126, the two selective EZH2 inhibitors in clinical trials, IHMT-337 showed comparable effects on H3K27me3 levels in different DLBCL cell lines in a dose-dependent manner (Fig. 1b). The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.